The trial achieved both of those its Key endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and top-quality enhancements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH when compared with placebo.1Distinct Populatio